ABN/ARSN

15 088 417 403

Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

Sigma Pharmaceuticals Limited

1	Type of buy-back Date Appendix 3C was given to ASX	On-market buy-back 13 September 2012	
		13 September 2012	
	of all shares/units bought been received, before, and	on, previous day	_
		Before previous day	Previous day
;	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	39,406,072	372,136
	Total consideration paid or payable for the shares/units	\$27,515,952	\$276,199

		Before p	reviou	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.7900	price	paid:	Highest price paid: \$0.7500
		Lowoot	prioc	paid:	Lowest price paid: \$0.7350
		\$0.6250	price	paiu.	Highest price allowed under rule 7.33: \$0.7833

How many shares/units may still be bought back?

6	If the company/trust has disclosed	78,852,144
	an intention to buy back a	
	maximum number of shares/units	
	- the remaining number of	
	shares/units to be bought back	

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.

Date: 24 April 2013

2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

(Director/Company secretary)

Print name: SUE MORGAN